Evoke Pharma (EVOK) Stock Price, Quote & News

Company Profile

Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was i...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 858 345 1494

Website: www.evokepharma.com

Address:

420 Stevens Avenue, Suite 230, Solana Beach, United States

Rain9991 Sep. 7 at 7:59 PM

$EVOK @resist, PT $ 5.36, $7, $9, then 10-12 if news, surge, luck

0 · Reply

BioTechChap Sep. 3 at 1:59 PM

$PHAT Not much talk about previously mentioned pipeline expansion/acquisitions today. Looks like $EVOK might be a suitable company to acquire. Anyone other thoughts?

1 · Reply

dbr_island Aug. 29 at 1:28 PM

$EVOK there it goes FLNT stop doubting this ticker 🚨🚨🚨🚨 I want $3 at MINIMUM 🎯✅ WATCH AND LEARN LIKE👇

0 · Reply

Messerschmittbf109 Aug. 27 at 9:33 PM

$CRVO $EVOK $IMMP $JSPR $VYNE of course -97 -99 my kids he would have done better . With his intuition.. So crazy people could pilot important companies and turnovers ,destroying them day after day

0 · Reply

Messerschmittbf109 Aug. 27 at 9:24 PM

$JSPR $CRVO $VYNE $IMMP $EVOK Except immutep + 24% in 5 years others have performance of 97-99% in 5 years Really embarrassing but board are in their stick seats …zero dignity

0 · Reply

AstroTradingGroup Aug. 27 at 4:34 AM

$EVOK gradually climbing, but watch for sharp reversals.

0 · Reply

Tradeforincome Aug. 26 at 5:49 PM

$EVOK going to need more than some BS partnership PR to pump this trash up. CEO needs to buy shares if he wants to move this.

0 · Reply

TA_Kongen Aug. 26 at 4:39 PM

$EVOK Curling, can we see some volume in this weird market?

1 · Reply

PirataCodex Aug. 26 at 2:13 PM

$EVOK crazy how this stock just sells off after a good PR .. 2x in a row now?? Maybe a correction is due

1 · Reply

PirataCodex Aug. 26 at 12:20 PM

$EVOK Anyone think this stock makes a run today?

0 · Reply

MAI Capital Management Announces Strategic Partnership with Evoke Advisors

Aug 26, 2025, 7:00 AM EDT - 13 days ago

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Aug 21, 2025, 7:00 AM EDT - 18 days ago

Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

Aug 6, 2025, 6:30 AM EDT - 4 weeks ago

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

Jul 9, 2025, 8:16 AM EDT - 2 months ago

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

May 13, 2025, 4:05 PM EDT - 4 months ago

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 8:30 AM EDT - 4 months ago

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

Mar 13, 2025, 8:36 PM EDT - 6 months ago

Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:02 PM EDT - 6 months ago

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 6, 2025, 8:30 AM EST - 6 months ago

Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

Feb 24, 2025, 8:30 AM EST - 6 months ago

Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

Dec 19, 2024, 8:30 AM EST - 9 months ago

Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

Dec 3, 2024, 8:30 AM EST - 9 months ago

Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

Nov 14, 2024, 8:00 AM EST - 10 months ago

InvestCloud to Partner with Evoke Advisors to Transform Their Digital Experience

Nov 7, 2024, 4:05 PM EST - 10 months ago

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

Oct 28, 2024, 12:34 PM EDT - 11 months ago

Evoke Pharma stock surges over 100%—here's why

Oct 23, 2024, 8:30 AM EDT - 11 months ago

Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

Oct 22, 2024, 8:30 AM EDT - 11 months ago

Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

Oct 1, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion

Sep 19, 2024, 2:20 PM EDT - 1 year ago

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

Sep 18, 2024, 4:00 PM EDT - 1 year ago

XLR8 America and EVoke Systems Partner to Deliver Smarter EV Charging Stations to the Parking Industry

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

Sep 4, 2024, 9:20 AM EDT - 1 year ago

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

Jul 30, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma, Inc. Announces Reverse Stock Split

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

May 16, 2024, 4:02 PM EDT - 1 year ago

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

May 14, 2024, 4:15 PM EDT - 1 year ago

Evoke Pharma Reports First Quarter 2024 Financial Results

Apr 17, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Mar 21, 2024, 4:15 PM EDT - 1 year ago

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

Mar 14, 2024, 9:33 PM EDT - 1 year ago

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 4:10 PM EST - 1 year ago

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

Feb 14, 2024, 7:30 AM EST - 1 year ago

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Feb 9, 2024, 7:30 AM EST - 1 year ago

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

Jan 29, 2024, 9:00 AM EST - 1 year ago

Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management

Nov 27, 2023, 8:30 AM EST - 1 year ago

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

Nov 14, 2023, 8:30 AM EST - 1 year ago

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

Nov 9, 2023, 8:30 AM EST - 1 year ago

Evoke Pharma Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma's Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

Aug 10, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

Jul 25, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting

Jun 14, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment

May 15, 2023, 4:05 PM EDT - 2 years ago

Evoke Pharma Reports First Quarter 2023 Financial Results

May 9, 2023, 7:00 AM EDT - 2 years ago

Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources

May 4, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma's Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023

Rain9991 Sep. 7 at 7:59 PM

$EVOK @resist, PT $ 5.36, $7, $9, then 10-12 if news, surge, luck

0 · Reply

BioTechChap Sep. 3 at 1:59 PM

$PHAT Not much talk about previously mentioned pipeline expansion/acquisitions today. Looks like $EVOK might be a suitable company to acquire. Anyone other thoughts?

1 · Reply

dbr_island Aug. 29 at 1:28 PM

$EVOK there it goes FLNT stop doubting this ticker 🚨🚨🚨🚨 I want $3 at MINIMUM 🎯✅ WATCH AND LEARN LIKE👇

0 · Reply

Messerschmittbf109 Aug. 27 at 9:33 PM

$CRVO $EVOK $IMMP $JSPR $VYNE of course -97 -99 my kids he would have done better . With his intuition.. So crazy people could pilot important companies and turnovers ,destroying them day after day

0 · Reply

Messerschmittbf109 Aug. 27 at 9:24 PM

$JSPR $CRVO $VYNE $IMMP $EVOK Except immutep + 24% in 5 years others have performance of 97-99% in 5 years Really embarrassing but board are in their stick seats …zero dignity

0 · Reply

AstroTradingGroup Aug. 27 at 4:34 AM

$EVOK gradually climbing, but watch for sharp reversals.

0 · Reply

Tradeforincome Aug. 26 at 5:49 PM

$EVOK going to need more than some BS partnership PR to pump this trash up. CEO needs to buy shares if he wants to move this.

0 · Reply

TA_Kongen Aug. 26 at 4:39 PM

$EVOK Curling, can we see some volume in this weird market?

1 · Reply

PirataCodex Aug. 26 at 2:13 PM

$EVOK crazy how this stock just sells off after a good PR .. 2x in a row now?? Maybe a correction is due

1 · Reply

PirataCodex Aug. 26 at 12:20 PM

$EVOK Anyone think this stock makes a run today?

0 · Reply

bandzja Aug. 26 at 11:41 AM

$EVOK very good news. 150 locations added through Omnicell partnership which specializes on gastroenterology practices. This nearly doubles the locations with dispencing GIMOTI. This will have a huge positive impact on revenue.

1 · Reply

Rampageusa Aug. 26 at 11:33 AM

$EVOK with volume we fly to 9.5/12

0 · Reply

GSP Aug. 26 at 11:25 AM

Gap play watch list for today (so far): $OPAD $SER $SATS $MRKR $EVOK .

1 · Reply

TA_Kongen Aug. 26 at 11:12 AM

$EVOK $MRKR $SER Watching pullbacks.

0 · Reply

DylanGFM Aug. 26 at 11:10 AM

$MRKR i knew damn well I wasn't going to trade it with the 200 that close. too weak to break out and hold over it. $EVOK did a round trip last time it dropped news also.

0 · Reply

Red2Greens Aug. 25 at 6:33 PM

$EVOK UTRX float reduction narrative plus crypto adjacency equals eyeballs watch market open sweeps then dips for entries risk stop below yesterday low trend intact ⚡️

0 · Reply

Sherrycat Aug. 25 at 4:01 PM

Biotech/Healthcare is heating up! 🔥 After tech’s massive run, rotation is real – money flowing into biotech plays like $BTAI $EVOK & $THAR & more. Strong earnings + undervalued setups = breakout potential. This sector is GREEN rn & looks ready for a major leg up. 🧬💉 #Biotech #Healthcare #Stocks

0 · Reply

JeffreyCress Aug. 24 at 11:13 PM

$EVOK

1 · Reply

Rampageusa Aug. 24 at 2:59 PM

$EVOK give it a month this will be 9++

1 · Reply

BioTechHealthX Aug. 24 at 2:45 PM

$EVOK With limited cash, rising debt, and no diversification, Evoke Pharma may be at breaking point. Investors should brace for downside risk. https://biotechhealthx.com/biotech-news/evoke-pharma-evok-faces-harsh-reality-can-it-avoid-collapse/

0 · Reply

Matzinger1 Aug. 22 at 5:51 PM

$EVOK Zoom out

0 · Reply

Thess5 Aug. 22 at 12:26 PM

$ELAB Out at $2.66. I don’t know what happened here. Big pick and gains. Made up for $EVOK

1 · Reply

Market Cap	8.12M
Revenue (ttm)	10.25M
Net Income (ttm)	-5.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52.20%
Debt to Equity Ratio	0.00

Volume	9,700
Avg Vol	3,105,422
Day's Range	N/A - N/A
Shares Out	1.56M
Stochastic %K	32%
Beta	-0.13
Analysts	Hold
Price Target	$10.00